Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03350477 | Nov 2017 → Nov 2018 | gastric cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT03350490 | Nov 2017 → Nov 2018 | intestinal cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT03239171 | Sep 2017 → Sep 2018 | small cell lung carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT03239158 | Sep 2017 → Sep 2018 | liver cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT03240224 | Sep 2017 → Sep 2018 | female breast carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT03239184 | Sep 2017 → Sep 2018 | pancreas disorder | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qilisheng | “In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months.” NCT03240224 ↗5“In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months.” NCT03239158 ↗ “The patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months.” NCT03239171 ↗ “"Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months.” NCT03239184 ↗ “"Qilisheng" Immunoregulatory Oral Solution” NCT03350477 ↗ “"Qilisheng" Immunoregulatory Oral Solution” NCT03350490 ↗ |
| Known as | "Qilisheng" Immunoregulatory Oral Solution | “"Qilisheng" Immunoregulatory Oral Solution” NCT03239184 ↗4“"Qilisheng" Immunoregulatory Oral Solution” NCT03240224 ↗ “"Qilisheng" Immunoregulatory Oral Solution” NCT03239171 ↗ “"Qilisheng" Immunoregulatory Oral Solution” NCT03350477 ↗ “"Qilisheng" Immunoregulatory Oral Solution” NCT03350490 ↗ |
| Route | Oral | “Each treatment: one bottle solution each day, consecutive 3 months, oral administration” NCT03239171 ↗ |